Increased plasma myeloperoxidase levels in systemic lupus erythematosus

Rheumatology International

Volumn 30, Issue 6, 2010, Pages 779-784

  Telles, Rosa Weiss ^a,b   Ferreira, Gilda Aparecida ^a   Da Silva, Neusa Pereira ^b   Sato, Emilia Inoue ^b,c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Brazilian Society of Cardiology   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Disease activity; Myeloperoxidase; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOPEROXIDASE; PREDNISONE;

ADULT; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISEASE ACTIVITY; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; PATIENT CODING; PRIORITY JOURNAL; RANK SUM TEST; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE OF ONSET; ANTIMALARIALS; ARTHRITIS; AZATHIOPRINE; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEROXIDASE; PREDNISONE; SEVERITY OF ILLNESS INDEX; UP-REGULATION; YOUNG ADULT;

EID: 77951022604     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1067-4     Document Type: Article

References (30)

1. Morgan PE, Sturgess AD, Davies MJ (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52:2069-2079
2. Cooke MS, Mistry N, Wood C et al (1997) Immunogenicity of DNA damage by reactive oxygen species: implications for anti- DNA antibodies in lupus. Free Radic Biol Med 22:151-159
3. Vaarala O (2000) Antibodies to oxidised LDL. Lupus 9:202-205
4. Obinger C (2006) Chemistry and biology of human peroxidases. Arch Biochem Biophys 445:197-198
5. O'Brien PJ (2000) Peroxidases. Chem Biol Interact 129:113-139
6. Ece A, Kelekçi S, Hekimoglu A et al (2007) Neutrophil activation, protein oxidation and ceruloplasmin levels in children with Henoch-Schonlein purpura. Pediatr Nephrol 22:1151-1157
7. Hansson GK (2005) InXammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
8. Brennan M-L, Penn MS, Lente FV et al (2003) Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604
9. Zhang R, Brennan M-L, Fu X et al (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142
10. Malle E, Buch T, Grone H-J (2003) Myeloperoxidase in kidney disease. Kidney Int 64:1956-1967
11. Wu CT, Eiserich JP, Ansari AA et al (2003) Myeloperoxidasepositive inXammatory cells participate in the bile duct in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology 38:1018-1025
12. Minota S, Horie S, Yamada A et al (1999) Circulating myeloperoxidase and anti-myeloperoxidase antibody in patients with vasculitis. Scand J Rheumatol 28:94-99
13. Schnabel A, Csernok E, Braun J et al (2000) Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegner's Granulomatosis. Am J Respir Crit Care Med 161:399-405
14. Accardo-Palumbo A, Triolo G, Carbone MC et al (2000) Polymorphonuclear leukocyte myeloperoxidase levels in patients with Behçet's disease. Clin Exp Rheumatol 18:495-498
15. Yazici C, Kose K, Calis M et al (2004) Increased advanced oxidation protein products in Behcet's disease: a new activity marker? Br J Dermatol 151:105-111
16. Milovanovic M, Nilsson E, Jaremo P (2004) Relationships between platelets and inXammatory markers in rheumatoid arthritis. Clin Chim Acta 343:237-240
17. Yazici C, Kose K, Calis M et al (2004) Protein oxidation status in patients with ankylosing spondylitis. Rheumatology 43:1235-1239
18. Rarok AA, Limburg PC, Kallenberg CG (2003) Neutrophilactivating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 74:3-15
19. Hess C, Sadallah S, SchiVerli JA (2000) Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. Blood 96:2822-2827
20. Sen D, Isenberg DA (2003) Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus 12:651-658
21. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classiWcation of the systemic lupus erythematosus (letter). Arthritis Rheum 40:1725
22. Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288-291
23. De la Fuente H, Richard-Patin Y, Jakez-Ocampo J et al (2001) Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus. Immunol Lett 77:175-180
24. Ren Y, Tang J, Mok MY et al (2003) Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 48:2888-2897
25. Heinecke JW (1999) Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inXammatory disorders. Lab Clin Med 133:321-325
26. Batuca JR, Ames PR, Isenberg DA et al (2007) Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann N Y Acad Sci 1108:137-146
27. Lau D, Mollnau H, Eiserich JP et al (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. PNAS 102:431-436
28. Torsteinsdottir I, Hakansson L, Hallgren R et al (1999) Serum lysozyme: a potential marker of monocyte/macrophage activity in rheumatoid arthritis. Rheumatology 38:1249-1254
29. Fontagne J, Roch-Arveiller M, Giroud JP et al (1889) EVects of some antimalarial drugs on rat inXammatory polymorphonuclear leukocyte function. Biomed Pharmacother 43:43-51
30. Fox R (1996) Antimalarial drugs: possible mechanism of action in autoimmune disease and prospects for drug development. Lupus 5(Suppl 1):S4-S10